Orforglipron

Obesity is becoming an increasingly serious public health problem globally, plaguing millions of people and significantly increasing their risk of chronic diseases such as diabetes and heart disease. In recent years, with the approval of new weight loss drugs such as Wegovy (Semaglutide) and Mounjaro (Tirzepatide), people's attention to this field has once again heated up, spawning an upsurge in the research and development of new treatments. There are currently nearly 70 obesity treatments in the research and development stage. Eli Lilly's Orforglipron is the world's first oral small molecule GLP-1RA to start Phase III clinical trials.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.